In which countries is Lisocabtagene maraleucel approved?

Overview of Lisocabtagene Maraleucel 
Lisocabtagene Maraleucel, also known by its trade name Breyanzi, is a second‐generation chimeric antigen receptor (CAR) T‐cell therapy product specifically engineered to target the CD19 antigen expressed on B cells. This therapy harnesses the patient’s own immune cells, which are collected and genetically modified to express a receptor that recognizes CD19, thereby enabling them to attack malignant B cells. Preclinical studies of liso-cel have underscored the importance of administering the product as a defined 1:1 ratio of CD4+ and CD8+ T cells, which together provide a coordinated anti-tumor response. This precise formulation enhances both the initial expansion and the long-lasting persistence of the CAR-T cells in the patient’s circulation, contributing to its robust antitumor activity and manageable toxicity profile.

Clinical Applications and Indications 
Clinically, Lisocabtagene maraleucel has been primarily evaluated in the setting of relapsed or refractory large B-cell lymphomas. Its indications span multiple aggressive B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma grade 3B, and transformed lymphoma. The landmark TRANSCEND NHL 001 trial demonstrated that liso-cel is both effective and safe, with high overall response rates and durable remissions in patients with heavily pretreated disease. The product’s ability to specifically target CD19 makes it an appealing option for patients whose lymphoma has not responded to conventional therapies including chemotherapy and autologous stem cell transplantation. Moreover, the defined cellular composition and the favorable balance between efficacy and manageable toxicity patterns position lisocabtagene maraleucel among the leading CAR-T cell therapies in the current therapeutic landscape.

Regulatory Approval Process

General Approval Process for Biologics 
Biologics such as Lisocabtagene maraleucel undergo a rigorous and systematic regulatory approval process that involves multiple phases of clinical testing, extensive analytical characterization, and a comprehensive review of manufacturing practices and clinical data. In the United States, the U.S. Food and Drug Administration (FDA) is responsible for assessing data that demonstrate the product’s quality, safety, and efficacy. The process typically involves a review of data from Phase 1 to Phase 3 clinical trials, thorough analytical and non-clinical reviews, and a final evaluation of the risk–benefit profile before granting approval. Similarly, in regions governed by the European Medicines Agency (EMA), a centralized regulatory procedure is followed whereby approvals by the European Commission enable the product’s marketing authorization across all EU member states.

Specific Requirements for CAR-T Therapies 
CAR-T therapies have unique characteristics that require additional regulatory considerations compared with conventional biologics. Because these products involve live, genetically modified cells, the evaluation extends well beyond conventional pharmacological and toxicological assessments. Regulators scrutinize the manufacturing process – including the collection, genetic modification, expansion, and quality control of autologous T cells – to ensure consistency and reliable performance. In addition, therapeutic aspects such as the risk of cytokine release syndrome (CRS) and neurotoxicity are critical components in the benefit–risk analysis of CAR-T therapies. The regulatory review therefore involves a tailored approach that assesses the cellular kinetics, persistence of the product, and detailed adverse event profiles as evidenced by comprehensive clinical data. This specialized assessment is essential in determining the therapeutic window and in ensuring that the product can be administered safely in diverse patient populations.

Approval Status of Lisocabtagene Maraleucel

Approved Countries 
Currently, Lisocabtagene maraleucel is approved in two major regions:

• United States: 
Lisocabtagene maraleucel is one of the three CAR-T cell products that have been granted approval by the U.S. Food and Drug Administration (FDA). The approval in the United States signifies that extensive clinical trial data demonstrating the product’s efficacy and safety were rigorously reviewed by the FDA before its market authorization. As detailed in various synapse-sourced materials, the FDA-approved status of liso-cel in the United States ensures its availability for treating relapsed or refractory large B-cell lymphomas, providing a crucial therapeutic option for patients with limited alternatives.

• European Union: 
In addition to the United States, Lisocabtagene maraleucel has also received approval from the European Commission, which is the regulatory body responsible for authorizing medicinal products across the European Union member states. For instance, Bristol Myers Squibb announced that the European Commission granted approval for Breyanzi (the trade name of lisocabtagene maraleucel) for the treatment of relapsed or refractory large B-cell lymphoma after one prior therapy. The European Commission’s approval is based on robust clinical data submitted for centralized review, and once granted, the approval allows for the commercialization of liso-cel across all EU member states. Although the data includes detailed information on pivotal trials and comprehensive efficacy and safety profiles, the approval by the European Commission ensures that patients within the entire European Economic Area now have access to this advanced CAR-T therapy.

Pending Approvals 
There are additional regulatory submissions and ongoing review processes in other territories, which are noteworthy even though formal approval has not yet been granted: 

• Japan: 
While clinical data from Japanese patients have been reported – such as in the TRANSCEND WORLD study where phase 2 results in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma were presented – there is currently no indication that lisocabtagene maraleucel has received formal approval by Japanese regulatory authorities. However, given the positive safety and efficacy profiles demonstrated in these studies, regulatory submissions are expected to be forthcoming, and future approval in Japan may follow as part of the global expansion of CAR-T therapies.

• Other Regions: 
Other potential markets, including Canada and select Asian countries or regions within the Asia-Pacific area, may be reviewing lisocabtagene maraleucel under their respective regulatory frameworks. As of the current data from our synapse sources, the primary approvals remain with the United States and the European Union; nevertheless, manufacturers may be in advanced stages of the submission process to regulatory bodies in these additional territories. The existence of overseas multicenter clinical trials and ongoing real-world studies suggests that further regulatory approvals are on the horizon once sufficient data have been collated and evaluated.

Implications of Approval

Impact on Patient Access 
The dual approval of Lisocabtagene maraleucel in the United States and the European Union has profound implications for patient access. In the United States, where the therapy is FDA-approved, patients with relapsed or refractory large B-cell lymphomas now have access to a treatment option that has demonstrated high overall response rates and sustained remissions. This approval is particularly critical for those patients who may have exhausted conventional therapies such as chemotherapy and stem cell transplantation. Similarly, in the European Union, the centralized nature of the European Commission’s approval means that patients in all EU member states obtain the benefit of early access through a harmonized regulatory pathway. Access to this advanced therapy is expected to improve survival rates and quality of life, while also reducing the long-term burden associated with repeated lines of conventional treatment. The fact that both regions have accepted and approved this product reinforces its role as a pioneering treatment modality in the era of personalized cell therapy.

Market Dynamics and Competition 
The approval of Lisocabtagene maraleucel has a significant impact on market dynamics within the CAR-T cell therapy space. With the product now available in the United States and European Union, it competes closely with other approved CAR-T therapies that target CD19, such as axicabtagene ciloleucel and tisagenlecleucel. Although all these products share the common target antigen, subtle differences in manufacturing processes, safety profiles, and administration protocols can influence product selection by clinicians and healthcare institutions. Lisocabtagene maraleucel’s unique approach of employing a fixed 1:1 ratio of CD4+ and CD8+ T cells is seen as a key differentiator that may contribute to improved durability of response and a more manageable safety profile. On a competitive front, its approval reinforces the trend toward personalized immunotherapy and encourages further innovations in cell therapy regimens. As more products become available through both on-label approvals and expanded indications, competitive pricing, innovative reimbursement strategies, and efforts to expand manufacturing capabilities are anticipated to shape the market landscape further.

Future Prospects and Research Directions 
Looking forward, the approval of Lisocabtagene maraleucel not only solidifies its current utility in treating high-risk B-cell malignancies but also opens an array of research avenues and potential indications. Ongoing and future clinical trials may explore combining lisocabtagene maraleucel with other agents (such as small molecule inhibitors or immune-modulatory therapies) to enhance its effectiveness and extend its duration of response. Additionally, the continued evaluation of CAR-T cell therapies in earlier lines of therapy, as well as in diverse patient populations including those with different subtypes of lymphoma or even in solid tumors, could further broaden its therapeutic application. Regulatory agencies in emerging markets will likely take note of the comprehensive clinical data already available from both the FDA and the European Commission submissions, potentially accelerating subsequent approvals internationally. Furthermore, advancements in manufacturing technology may allow for reduced production times and scalable production models, which are expected to foster both increased patient access and optimized treatment outcomes over time.

In addition, real-world data collection and post-approval monitoring will contribute valuable insights into long-term efficacy and safety, providing the foundation for iterative improvements in CAR-T cell therapy protocols. This continuous feedback from clinical practice will be crucial in refining patient selection criteria and mitigating adverse events such as cytokine release syndrome and neurotoxicity, thus ensuring that such innovative therapies remain both effective and safe for routine clinical use.

Conclusion 
In summary, Lisocabtagene maraleucel is currently approved in the United States and the European Union. The product’s FDA approval in the United States and its approval by the European Commission underscore its robust clinical performance in treating relapsed or refractory large B-cell lymphomas and its capacity to provide a durable response with a manageable safety profile. These approvals have significant implications for patient access by making an advanced cell therapy widely available in two of the most influential healthcare markets globally. Moreover, the approval marks a major milestone in the competitive CAR-T therapy landscape, where products are continuously evolving to offer even more effective and safer treatment options. While regulatory clearance in other regions such as Japan and select emerging markets is still pending, ongoing clinical trials and real-world data collection signal that further approvals could be forthcoming in the near future.

This development has a multifaceted impact: it not only provides a new lifeline for patients with limited treatment options but also sets the stage for competitive dynamics that drive innovation, expand treatment alternatives, and improve clinical outcomes. Future research is poised to explore combination therapies, early-line usage, and broader indications, thereby reinforcing the promising potential of CAR-T cell therapy. 

Thus, with regulatory approvals in the United States and the European Union, Lisocabtagene maraleucel currently enjoys a strong foothold in key markets, and its expanding role in clinical practice will likely pave the way for global access as additional regulatory submissions are successful. This represents a significant advancement in the field of immunotherapy and a hopeful step forward for patients battling aggressive B-cell malignancies.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.